Copaxone's Invalidated Patents Don't Alter Our Outlook for Teva
Since we had already viewed Teva’s patents on Copaxone 40 mg as particularly weak, we’re not surprised by the announcement that the patents have been invalidated in a U.S. District Court decision. The timing of a generic launch remains uncertain due to one last lingering patent and the lack of a tentative approval of a generic version by the Food and Drug Administration, but we still anticipate generic competition on Copaxone will emerge in the near term. Novartis and Momenta seem particularly w...
Morningstar, Inc. is a leading provider of independent investment research in North America, Europe, Australia, and Asia. The company offer an extensive line of products and services for individual investors, financial advisors, asset managers, and retirement plan providers and sponsors.
Morningstar provides data on approximately 530,000 investment offerings, including stocks, mutual funds, and similar vehicles, along with real-time global market data on more than 18 million equities, indexes, futures, options, commodities, and precious metals, in addition to foreign exchange and Treasury markets. Morningstar also offers investment management services through its investment advisory subsidiaries and had approximately $185 billion in assets under advisement and management as of June 30, 2016.
We have operations in 27 countries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.